本文選題：替格瑞洛 + 替非羅班��； 參考：《中國(guó)藥房》2017年32期

【摘要】：目的:比較氯吡格雷與替格瑞洛治療急性非ST段抬高型心肌梗死(NSTEMI)的臨床療效及安全性。方法:收集2013年10月-2015年11月我院心內(nèi)科收治的NSTEMI患者160例,按隨機(jī)數(shù)字表法分為觀察組和對(duì)照組,各80例。兩組患者均給予常規(guī)治療,并以0.05μg/(kg·h)持續(xù)靜脈泵入鹽酸替非羅班氯化鈉注射液等,對(duì)照組在常規(guī)治療基礎(chǔ)上口服負(fù)荷劑量的硫酸氯吡格雷片300 mg,之后劑量改為75 mg,qd;觀察組在常規(guī)治療的基礎(chǔ)上口服負(fù)荷劑量的替格瑞洛片180 mg,之后改為90 mg,bid。兩組患者均治療1個(gè)月。比較兩組患者治療前后血小板集聚率、左室射血分?jǐn)?shù)(LVEF)、左室舒張末期內(nèi)徑(LVEDD)、纖維蛋白原水平,以及主要心血管事件(MACE)和出血事件發(fā)生率。結(jié)果:治療前,兩組患者血小板集聚率比較,差異無(wú)統(tǒng)計(jì)學(xué)意義(P0.05);治療1周及1個(gè)月后,兩組患者血小板集聚率顯著降低,且觀察組顯著低于對(duì)照組,差異均有統(tǒng)計(jì)學(xué)意義(P0.05)。治療1周后,兩組患者LVEF、LVEDD水平比較,差異無(wú)統(tǒng)計(jì)學(xué)意義(P0.05);治療1個(gè)月后,觀察組患者LVEF顯著升高,且顯著高于對(duì)照組,對(duì)照組患者LVEDD顯著降低且顯著低于觀察組,差異均有統(tǒng)計(jì)學(xué)意義(P0.05)。治療前、治療3 d后,兩組患者纖維蛋白原水平比較,差異無(wú)統(tǒng)計(jì)學(xué)意義(P0.05);治療1周、1個(gè)月后,兩組患者纖維蛋白原水平均顯著降低,且觀察組顯著低于對(duì)照組,差異均有統(tǒng)計(jì)學(xué)意義(P0.05)。觀察組患者M(jìn)ACE事件發(fā)生率為11.25%,顯著低于對(duì)照組的25.00%,差異有統(tǒng)計(jì)學(xué)意義(P0.05);兩組患者出血率比較(3.75%vs.7.50%),差異無(wú)統(tǒng)計(jì)學(xué)意義(P0.05)。結(jié)論:與氯吡格雷比較,替格瑞洛能有效抑制NSETMI患者血小板集聚,降低纖維蛋白原水平,提高心功能,改善預(yù)后,同時(shí)并未增加出血風(fēng)險(xiǎn),安全性較高。
[Abstract]:Objective: to compare the efficacy and safety of clopidogrel and tigrilol in the treatment of acute non-St segment elevation myocardial infarction (NSTEMI). Methods: from October 2013 to November 2015, 160 patients with NSTEMI were randomly divided into two groups: observation group (n = 80) and control group (n = 80). The patients in both groups were treated with routine therapy and were continuously injected with tefebene hydrochloride sodium chloride injection with 0. 05 渭 g/(kg / h. In the control group, the loading dose of clopidogrel sulfate was 300 mg, then the dose was 75 mg / qd, and the observation group was treated with the loading dose of tigrilol 180 mg and 90 mg / kg respectively on the basis of routine treatment. Both groups were treated for 1 month. Platelet aggregation rate, left ventricular ejection fraction (LVEF), left ventricular end-diastolic diameter (LVEDDN), fibrinogen level, major cardiovascular events (MACEE) and incidence of bleeding events were compared between the two groups before and after treatment. Results: before treatment, there was no significant difference in platelet aggregation rate between the two groups, but after one week and one month of treatment, the platelet aggregation rate in the two groups was significantly lower than that in the control group, and the difference was statistically significant (P 0.05). After one week of treatment, there was no significant difference in LVEF and LVEDD levels between the two groups. After one month of treatment, the LVEF of the observation group was significantly higher than that of the control group, and the LVEDD of the control group was significantly lower and significantly lower than that of the observation group. The difference was statistically significant (P 0.05). Before and 3 days after treatment, there was no significant difference in fibrinogen level between the two groups, but the fibrinogen level in the observation group was significantly lower than that in the control group after one week and one month of treatment, and the level of fibrinogen in the two groups was significantly lower than that in the control group. The difference was statistically significant (P 0.05). The incidence of MACE events in the observation group was 11.25, which was significantly lower than that in the control group (25.00), the difference was statistically significant (P 0.05), and the bleeding rate of the two groups was 3.75 vs.7.50 and there was no significant difference between the two groups (P 0.05). Conclusion: compared with clopidogrel, tigrilol can effectively inhibit platelet aggregation, decrease fibrinogen level, improve cardiac function and improve prognosis in patients with NSETMI without increasing the risk of bleeding.
【作者單位】： 長(zhǎng)沙市第一醫(yī)院心血管內(nèi)科;
【分類號(hào)】：R542.22

【相似文獻(xiàn)】

相關(guān)博士學(xué)位論文 前4條

1 張麗娜;遺傳變異與PCI術(shù)后冠心病患者臨床預(yù)后的關(guān)系及多種遺傳位點(diǎn)檢測(cè)方法比較[D];華中科技大學(xué);2015年

2 王浩然;CYP2C19*2基因型對(duì)氯吡格雷抗血小板聚集作用及體內(nèi)活性代謝產(chǎn)物濃度的影響[D];華中科技大學(xué);2015年

3 趙香梅;發(fā)病至首次醫(yī)療接觸在3-6小時(shí)急性ST段抬高心肌梗死患者靜脈溶栓和轉(zhuǎn)診PCI的預(yù)后分析[D];鄭州大學(xué);2017年

4 劉歌;干細(xì)胞表面工程化促進(jìn)梗死心肌再血管化的研究[D];第三軍醫(yī)大學(xué);2017年

相關(guān)碩士學(xué)位論文 前2條

1 張清麗;心梗特征提取與輔助診斷模型研究[D];鄭州大學(xué);2017年

2 孟楊;P2Y12抑制劑在接受DAPT治療的氯吡格雷低反應(yīng)性患者中的有效性及安全性評(píng)價(jià)[D];鄭州大學(xué);2017年

，

本文編號(hào)：1859017